among 95 CMV-seropositive patients receiving CD19 CAR T-cell therapy for aggressive B cell lymphoma, 42(44%) patients had at least one positive serum CMV viral PCR; only 7 patients received preemptive antiviral treatment, and no CMV end-organ disease was reported (65). Here, CD19 is linked to B-cell non-Hodgkin lymphoma.